Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 2,3-Diphosphoglycerate (2,3-DPG) synthesis pathway, also known as the Luebering-Rapoport shunt, is a metabolic pathway within red blood cells that regulates hemoglobin's affinity for oxygen. It involves the conversion of 1,3-bisphosphoglycerate to 2,3-BPG by bisphosphoglycerate mutase and the subsequent hydrolysis of 2,3-BPG to 3-phosphoglycerate by bisphosphoglycerate phosphatase. This pathway is crucial for adapting to hypoxic conditions and ensuring efficient oxygen delivery to tissues.
N/A
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 2,3-Diphosphoglycerate Synthesis Pathway (2,3-DPG Synthesis Pathway).